Available Programs > Online On-Demand

PROGRAM OVERVIEW Invasive mold infections are a significant cause of morbidity and mortality due to the increasing population of immunocompromised patients and newly identified risk factors beyond malignancy and immunosuppression. Through real-world case studies and discussion, Dr Peter Pappas and Dr Stephen Threlkeld will address the key challenges faced by community-based and rural clinicians, including: shifting trends in the fungal landscape with a focus on Aspergillus spp. and Mucorales; recognizing and diagnosing these infections; and the importance of prompt, informed,…

PROGRAM OVERVIEW The landscape of genetic testing and treatment for inherited retinal diseases (IRDs) is rapidly evolving. Keeping up to date on clinical trials, ordering and interpreting genetic test results, and knowing how and when to best collaborate with genetic counselors can be a challenge for ophthalmologists, retina specialists, and optometrists. In this interactive activity, experts in retinal disease and genetic counseling discuss challenges and opportunities to enhance collaborative patient care, including 2 compelling IRD cases. TARGET AUDIENCE General ophthalmologists…

Goal: To educate pharmacists about MS pathophysiology and the new American Academy of Neurology recommendations for the use of disease-modifying therapies (DMTs) in adults. Educational Objectives: Upon completion of this activity, participants should be better able to: DESCRIBE the pathophysiological mechanisms that contribute to multiple sclerosis (MS) EVALUATE the safety and efficacy of available disease-modifying therapies EMPLOY care coordination strategies that emphasize multidisciplinary collaboration and advocacy for individuals with MS DEFINE the pharmacist's role in providing drug management and administrative…

Direct factor Xa (FXa) inhibitors (rivaroxaban, apixaban, edoxaban, and betrixaban) have become the most widely utilized class of anticoagulants in the United States. Due to their expertise in managing anticoagulation and their role as the drug information experts, pharmacists are critically important in assuring the correct FXa inhibitor is being used in the correct indication, at the correct dose, with detailed patient education to maximize positive patient outcomes. They must also be able to recognize and manage bleeds that are…

Treatment selection and modification in MS can be a complex, daunting problem for MS care providers. Enjoy active discussion with your colleagues and get expert insight into optimizing outcomes for your patients on infusible MS therapies! Join us to discuss thought-provoking, real-world cases with your peers and a clinical expert in MS. This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC), the International Organization of Multiple Sclerosis Nurses (IOMSN), and Spire Learning. This activity is supported by…

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a lifetime prevalence of 10% to 20% in children and 1% to 3% in adults. It is the most common pediatric skin disease and primary care providers (PCPs) are often the first point of contact for the diagnosis and management of AD symptoms. As many as 70% of patients with mild to moderate disease can be managed in the primary care setting. This case activity addresses the latest in…

An increasing number of people are taking oral anticoagulants (OACs), and major bleeds or emergent surgeries in these individuals are a challenge to safely and effectively manage. Newer reversal agents that target direct oral anticoagulants have changed the treatment landscape. Clinicians must assess each case and consider the most recent evidence on reversal strategies to recommend an optimal treatment plan. This 30-minute, certified activity will address important clinical issues related to managing bleeds in patients receiving OACs, including evaluating bleed…

Seasonal influenza has a significant socioeconomic impact, with several patient populations at high risk of complications. This podcast will provide the latest updates in the prevention and management of influenza and insights into opportunities for improved patient care, considerations for diagnostic testing, and efficacy and safety of antivirals. https://learning.freecme.com/a/34424P2N9tAD  

Improved understanding of renal cell carcinoma (RCC) has led to the recent approval of immuno-oncology therapies (IOs) that can be used in combination with other IOs or with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs). In this interactive webinar experts in RCC discuss IO combinations in RCC, including the rationale for development, clinical trial data, and safety considerations concerning immune-related adverse events. This activity includes interactive polling questions interspersed throughout the activity to engage learners and facilitate application…

Tenosynovial giant cell tumor (TGCT) is a rare, nonmalignant tumor affecting the synovial lining of joints, bursae, and tendon sheaths. It is a potentially locally aggressive disease with high recurrence rates. In addition to agents used off-label for TGCT, the FDA recently approved the first medication specifically indicated for adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. This educational activity will ensure clinicians are better informed of the benefits…

There is a lack of therapeutic options for the management of myeloid malignancies. So what are some emerging therapies that are available to patients? Join Mikkael A. Sekeres, MD, MS, and Sara M. Tinsley, PhD, ARNP, AOCNP during this podcast discussion and find out what novel therapeutic approaches are being evaluated for myeloid malignancies. This activity is jointly provided by Albert Einstein, Montefiore, and Spire Learning. This activity is supported by an independent educational grant from Takeda Oncology. Click on…

How have PARP inhibitors changed maintenance therapy for advanced ovarian cancer? Join Dr Michael Birrer and Dr Ursula Matulonis as they discuss recent clinical data related to the use of PARP inhibitors in maintenance therapy for advanced ovarian cancer, and highlight strategies to effectively prevent and manage treatment-related adverse effects. This activity is jointly provided by Postgraduate Institute for Medicine and Spire Learning. This activity is supported by an independent educational grant from Tesaro, a GSK company.   Click on this link to…

How have PARP inhibitors changed maintenance therapy for advanced ovarian cancer? Join Dr Michael Birrer and Dr Ursula Matulonis as they discuss recent clinical data related to the use of PARP inhibitors in maintenance therapy for advanced ovarian cancer, and highlight strategies to effectively prevent and manage treatment-related adverse effects. This activity is jointly provided by Postgraduate Institute for Medicine and Spire Learning. This activity is supported by an independent educational grant from Tesaro, a GSK company. Click on this link to access…

Are you confident selecting between available therapies for hemophilia A? Over the past few decades, the care for patients with hemophilia A has drastically improved, while also becoming more complex, with the advent of new therapeutic options for this challenging disease. This educational activity reviews FDA-approved and investigational products used for this disease and the corresponding data for these agents. Jordan A. Shavit, M.D., Ph.D. Medical Oncologist, Sarcoma Oncology Center Santa Monica, CA Medical Advisor, Hemophilia Foundation of Southern California…